HRP20040964A2 - Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation - Google Patents
Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation Download PDFInfo
- Publication number
- HRP20040964A2 HRP20040964A2 HR20040964A HRP20040964A HRP20040964A2 HR P20040964 A2 HRP20040964 A2 HR P20040964A2 HR 20040964 A HR20040964 A HR 20040964A HR P20040964 A HRP20040964 A HR P20040964A HR P20040964 A2 HRP20040964 A2 HR P20040964A2
- Authority
- HR
- Croatia
- Prior art keywords
- reported
- particles
- pharmaceutical formulations
- corticosteroid
- sterilized
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 36
- 239000000725 suspension Substances 0.000 title claims description 30
- 230000008569 process Effects 0.000 title claims description 22
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000003246 corticosteroid Substances 0.000 title claims description 12
- 239000013543 active substance Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000009826 distribution Methods 0.000 claims description 15
- 239000007900 aqueous suspension Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 8
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 229960000676 flunisolide Drugs 0.000 claims description 3
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
- 241000282341 Mustela putorius furo Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000000779 smoke Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- -1 dipropionate (BDP) Chemical compound 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002MI000808A ITMI20020808A1 (it) | 2002-04-17 | 2002-04-17 | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione |
| PCT/EP2003/003916 WO2003086347A1 (fr) | 2002-04-17 | 2003-04-15 | Procede de preparation d'une suspension sterile de particules de corticosteroides, destinee a etre administree par inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040964A2 true HRP20040964A2 (en) | 2005-02-28 |
Family
ID=11449718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040964A HRP20040964A2 (en) | 2002-04-17 | 2004-10-14 | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7541021B2 (fr) |
| EP (1) | EP1494647B1 (fr) |
| CN (1) | CN1292733C (fr) |
| AR (1) | AR039317A1 (fr) |
| AT (1) | ATE338539T1 (fr) |
| AU (1) | AU2003227627A1 (fr) |
| BR (1) | BRPI0304821B8 (fr) |
| CA (1) | CA2481520C (fr) |
| CY (1) | CY1105800T1 (fr) |
| DE (1) | DE60308164T2 (fr) |
| DK (1) | DK1494647T3 (fr) |
| EA (1) | EA007629B1 (fr) |
| ES (1) | ES2272987T3 (fr) |
| HK (1) | HK1079986B (fr) |
| HR (1) | HRP20040964A2 (fr) |
| IT (1) | ITMI20020808A1 (fr) |
| MA (1) | MA27194A1 (fr) |
| MX (1) | MXPA04010117A (fr) |
| PE (1) | PE20030948A1 (fr) |
| PL (1) | PL207863B1 (fr) |
| PT (1) | PT1494647E (fr) |
| SI (1) | SI1494647T1 (fr) |
| UA (1) | UA79453C2 (fr) |
| WO (1) | WO2003086347A1 (fr) |
| ZA (1) | ZA200408319B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4755495B2 (ja) * | 2002-12-12 | 2011-08-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 組合せ医薬品 |
| WO2005025578A1 (fr) * | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Utilisation de ciclesonide dans le traitement de maladies respiratoires |
| BRPI0415531B8 (pt) | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| WO2005102354A1 (fr) * | 2004-04-20 | 2005-11-03 | Altana Pharma Ag | Utilisation de ciclesonide pour le traitement des maladies respiratoires chez des patients fumeurs |
| GB0425266D0 (en) | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
| EP1683514B1 (fr) | 2005-01-20 | 2012-05-23 | Eratech S.r.l. | Procédé de préparation de suspensions concentrées et une trousse de ceci |
| CA2622758A1 (fr) * | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Formulations aripiprazoliques nanoparticulaires |
| US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
| WO2007095341A2 (fr) * | 2006-02-15 | 2007-08-23 | Tika Läkemedel Ab | Stérilisation de corticostéroïdes avec perte réduite de masse |
| PT2170348T (pt) * | 2007-06-22 | 2016-11-02 | Dompé Farm S P A | Comprimidos efervescentes para utilização por via inalatória |
| AR067747A1 (es) * | 2007-07-31 | 2009-10-21 | Otsuka Pharma Co Ltd | Metodos para producir suspension de aripiprazol y formulacion liofilizada |
| CN102657659A (zh) * | 2010-11-23 | 2012-09-12 | 天津金耀集团有限公司 | 皮肤用含有辅料的丙酸氟替卡松与含有辅料的水的透皮吸收药物 |
| CN102475708A (zh) * | 2010-11-23 | 2012-05-30 | 天津金耀集团有限公司 | 丙酸氟替卡松和含辅料的水构成的治疗皮肤病的分离式水混悬剂药物 |
| LT2704724T (lt) | 2011-05-03 | 2017-01-10 | Chiesi Farmaceutici S.P.A. | Pagerinta beklometazono dipropionato suspensijos kompozicija, skirta įvesti inhaliaciniu būdu |
| CN103505412A (zh) * | 2012-06-26 | 2014-01-15 | 上海臣邦医药科技有限公司 | 一种吸入用丙酸氟替卡松混悬液的制备方法 |
| WO2022098321A1 (fr) * | 2020-11-09 | 2022-05-12 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Procédé de préparation de suspensions stérilisées pour l'administration par inhalation |
| WO2022231531A1 (fr) * | 2021-04-29 | 2022-11-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Procédé de préparation de suspensions stérilisées pour inhalation par nébulisation |
| WO2022231533A1 (fr) * | 2021-04-29 | 2022-11-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Procédé pour la préparation de suspensions stérilisées pour l'inhalation par nébulisation |
| WO2023022672A2 (fr) * | 2021-08-18 | 2023-02-23 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Procédé de préparation de suspensions homogènes pour inhalation par nébulisation |
| WO2024180569A1 (fr) * | 2023-03-01 | 2024-09-06 | Ajaykumar Balraj Kanduri | Suspension de nébulisation aqueuse synergique pour la gestion de troubles respiratoires infectieux et processus de préparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303692B1 (it) * | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
| ITMI20022674A1 (it) * | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
-
2002
- 2002-04-17 IT IT2002MI000808A patent/ITMI20020808A1/it unknown
-
2003
- 2003-04-15 EA EA200401209A patent/EA007629B1/ru unknown
- 2003-04-15 ES ES03725033T patent/ES2272987T3/es not_active Expired - Lifetime
- 2003-04-15 AT AT03725033T patent/ATE338539T1/de active
- 2003-04-15 PL PL373331A patent/PL207863B1/pl unknown
- 2003-04-15 BR BRPI0304821A patent/BRPI0304821B8/pt not_active IP Right Cessation
- 2003-04-15 DE DE60308164T patent/DE60308164T2/de not_active Expired - Lifetime
- 2003-04-15 MX MXPA04010117A patent/MXPA04010117A/es active IP Right Grant
- 2003-04-15 UA UA20041008327A patent/UA79453C2/uk unknown
- 2003-04-15 EP EP03725033A patent/EP1494647B1/fr not_active Expired - Lifetime
- 2003-04-15 US US10/510,232 patent/US7541021B2/en not_active Expired - Fee Related
- 2003-04-15 DK DK03725033T patent/DK1494647T3/da active
- 2003-04-15 AU AU2003227627A patent/AU2003227627A1/en not_active Abandoned
- 2003-04-15 WO PCT/EP2003/003916 patent/WO2003086347A1/fr active IP Right Grant
- 2003-04-15 CA CA2481520A patent/CA2481520C/fr not_active Expired - Fee Related
- 2003-04-15 PT PT03725033T patent/PT1494647E/pt unknown
- 2003-04-15 CN CNB038111608A patent/CN1292733C/zh not_active Expired - Lifetime
- 2003-04-15 SI SI200330532T patent/SI1494647T1/sl unknown
- 2003-04-16 PE PE2003000389A patent/PE20030948A1/es not_active Application Discontinuation
- 2003-04-16 AR ARP030101350A patent/AR039317A1/es unknown
-
2004
- 2004-10-08 MA MA27897A patent/MA27194A1/fr unknown
- 2004-10-14 ZA ZA200408319A patent/ZA200408319B/xx unknown
- 2004-10-14 HR HR20040964A patent/HRP20040964A2/hr not_active Application Discontinuation
-
2006
- 2006-01-04 HK HK06100045.9A patent/HK1079986B/zh not_active IP Right Cessation
- 2006-11-21 CY CY20061101689T patent/CY1105800T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040964A2 (en) | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation | |
| KR100783096B1 (ko) | 흡입운반을 위한 약제입자의 현탁물 제조방법 및 이를 이용한 무균화된 미분화 베클라메타손 디프로피오네이트 | |
| CN102319209B (zh) | 鼻用药物制剂和使用方法 | |
| EA012388B1 (ru) | Водные суспензии циклесонида для аэрозольного распыления | |
| US6187765B1 (en) | Mometasone furoate suspensions for nebulization | |
| CN108175763B (zh) | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 | |
| EP1033991A1 (fr) | Suspensions de mometasone furoate pour la nebulisation | |
| DK2704724T3 (en) | Improved suspension formulation of beclomethasone dipropionate for administration by inhalation | |
| CN108175764A (zh) | 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 | |
| ES2388287T3 (es) | Procedimiento para la preparación de suspensiones concentradas de fármacos y kit correspondiente | |
| CN112137957B (zh) | 一种药用吸入气雾剂及其制备方法 | |
| WO2022231531A1 (fr) | Procédé de préparation de suspensions stérilisées pour inhalation par nébulisation | |
| Kumar et al. | Engineering Budesonide Microparticles for Enhancing Pulmonary Targeting: Validation through In Vivo Investigations | |
| Ali et al. | Assessment of Critical Quality Attributes of Budesonide and Formoterol Fumarate Dihydrate in Dry Powder Inhalers Marketed in Pakistan. | |
| TR2023013885T2 (tr) | Nebuli̇zasyon yoluyla i̇nhalasyon i̇çi̇n steri̇li̇ze edi̇lmi̇ş süspansi̇yonlarin hazirlanmasi yöntemi̇ | |
| WO2022098321A1 (fr) | Procédé de préparation de suspensions stérilisées pour l'administration par inhalation | |
| TR2023005107T2 (tr) | İnhalasyon yoluyla kullanim i̇çi̇n steri̇li̇ze süspansi̇yonlarin hazirlanmasina i̇li̇şki̇n yöntem | |
| US20150290220A1 (en) | Pharmaceutical formualtions comprising a Gluococorticosteroid | |
| MXPA00003476A (en) | Mometasone furoate suspensions for nebulization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20050406 Year of fee payment: 3 |
|
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |